2 terminated. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Terminated 2 |
Follow Metastatic Melanoma: new trials by email Literature Review of Metastatic Melanoma trials Research Report on Metastatic Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma High Dose Interleukin-2, Ipilimumab - Metastatic Melanoma | Phase 4 | Terminated | Clinigen, Inc. | 29 | 2013-05-01 | 2023-12-05 |
| HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma vemurafenib + HD IL-2 - Metastatic Melanoma | Phase 4 | Terminated | Clinigen, Inc. | 53 | 2012-08-01 | 2021-02-01 |
Melanoma (2) · Skin Neoplasms (2) · Neoplasm Metastasis (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
aldesleukin (2) · Interleukin-2 (1) · Interleukins (1) · Ipilimumab (1) · Vemurafenib (1)
Clinigen, Inc. (2)
United States (2)
James Lowder, MD (1) · Sapna Patel, MD (1) · Tharak Rao, MD (1) · William Sharfman, MD (1)